Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Edelstein

Pediatric Gastroenterology Beverly Hills, CA Medical Doctor

NPI 1962532796 CMS profile 134023

150 N Robertson Blvd, Suite 204, Beverly Hills, CA 90211

Open in the dashboard

General payments

$3,976

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Edelstein of Beverly Hills, CA is reported in the CMS Open Payments database as having received $3,976 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $649 28
2024 General $827 36
2023 General $1,004 40
2022 General $434 21
2021 General $372 20
2020 General $356 16
2019 General $333 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Edelstein
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Susan Edelstein were reported at $649. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Susan Edelstein Pediatric Gastroenterology median Middle half National median
2019 $333 $131 $41–$311 $163
2020 $356 $79 $23–$223 $114
2021 $372 $104 $32–$321 $132
2022 $434 $125 $37–$331 $149
2023 $1,004 $169 $55–$440 $160
2024 $827 $196 $73–$563 $164
2025 $649 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $1,727 85 payments
  2. QOL Medical, LLC $371 14 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $266 14 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $246 11 payments
  5. Regeneron Healthcare Solutions, Inc. $240 10 payments
  6. Exact Sciences Corporation $187 7 payments
  7. Genzyme Corporation $181 7 payments
  8. AbbVie, Inc. $167 7 payments
  9. Ferring Pharmaceuticals Inc. $122 1 payment
  10. Mirum Pharmaceuticals, Inc. $88 4 payments
  11. Other $380 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,961 175 payments
  2. Education $15 3 payments
Products named General payments · program years 2019–2025
  1. INJECTAFER $1,662 82 payments
  2. XIFAXAN $266 14 payments
  3. DUPIXENT Inflammation And Immunology $201 8 payments
  4. Cologuard Collection Kit $187 7 payments
  5. DUPIXENT Immunology $181 7 payments
  6. Sucraid Therapy For Csid $151 5 payments
  7. Sucraid Genetic Disease $127 5 payments
  8. REBYOTA $122 1 payment
  9. Sucraid Therapy For Csid $93 4 payments
  10. Livmarli $88 4 payments
  11. Other $984 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record